Roquefte's H1 2025 Performance Outshines Market Expectations

Roquefte has reported robust results for the first half of 2025, amidst challenging market conditions. The company highlighted a 4% increase in turnover, reaching €2,371 million, and an 18% rise in EBITDA to €294 million. This growth was fueled by the consolidation of IFF Pharma Solutions since May 1, 2025, and an advantageous product mix.

The successful acquisition of IFF Pharma Solutions marked a significant milestone, strengthening Roquefte’s operational model. The Health & Pharma Solutions division benefited greatly from this acquisition, which offset weaker performance in the capsule segment.

Meanwhile, the Nutrition & Bioindustry segment achieved solid results due to sustained demand for specialty products, improving EBITDA margin significantly through effective pricing and cost management strategies. Despite facing a volatile macroeconomic environment, Roquefte remains committed to executing its strategic focuses, including operational excellence and innovation, to drive profitability and stakeholder value.